The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | PV-PINPOINT: a study investigating the diagnosis and management of polycythemia vera in the UK
Mary Frances McMullin, MD, Queen’s University, Belfast, UK, shares insights from the PV-PINPOINT study conducted in the UK to assess the diagnosis and management of polycythemia vera (PV). The study found good adherence to guidelines for diagnosis and symptom assessment but highlighted unmet needs, primarily the lack of a cure. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Novartis, BMS, GSK; Speaker Bureau: Novartis, GSK, Incyte; Clinical Trial Support: BMS.
